Close Menu

NEW YORK – Fulgent Genetics reported after the close of the market on Monday a 44 percent increase in first quarter revenues driven by a large jump in billable test numbers. The firm also withdrew its 2020 full-year revenue guidance.

For the three months ended March 31, Fulgent posted revenues of $7.8 million versus $5.4 million in the same quarter last year. The firm said it delivered 13,163 billable genetic tests during Q1, a 75 percent increase year over year.

To read the full story....

...and receive Daily News bulletins.

Already have a 360Dx or GenomeWeb account?
Login Now.

Don't have a 360Dx or GenomeWeb account?
Register for Free.